amifostine anhydrous has been researched along with Esophageal Neoplasms in 5 studies
Amifostine: A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia.
amifostine : An organic thiophosphate that is the S-phospho derivative of 2-[(3-aminopropyl)amino]ethanethiol. A prodrug for the free thiol, WR-1065, which is used as a cytoprotectant in cancer chemotherapy and radiotherapy.
Esophageal Neoplasms: Tumors or cancer of the ESOPHAGUS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Most patients with locally advanced esophageal cancer die from their disease, despite complete surgical extirpation of tumor or institution of aggressive, multimodality treatment." | 2.42 | Aggressive multimodality therapy for patients with locally advanced esophageal cancer: is there a role for amifostine? ( Jatoi, A, 2003) |
| "Transient hypotension was the most common side effect occurring in association with amifostine." | 1.31 | Tolerability of the cytoprotective agent amifostine in elderly patients receiving chemotherapy: a comparative study. ( Genvresse, I; Harder, H; Lange, C; Possinger, K; Schanz, J; Schweigert, M; Späth-Schwalbe, E, 2001) |
| "Esophageal cancer is treated optimally with a combined-modality approach according to most clinical investigators." | 1.31 | Esophageal cancer and the esophagus: challenges and potential strategies for selective cytoprotection of the tumor-bearing organ during cancer treatment. ( Jatoi, A; Thomas, CR, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jatoi, A | 2 |
| Kutter, J | 1 |
| Ozsahin, M | 1 |
| Monnier, P | 1 |
| Stupp, R | 1 |
| Genvresse, I | 1 |
| Lange, C | 1 |
| Schanz, J | 1 |
| Schweigert, M | 1 |
| Harder, H | 1 |
| Possinger, K | 1 |
| Späth-Schwalbe, E | 1 |
| Maurici, D | 1 |
| Monti, P | 1 |
| Campomenosi, P | 1 |
| North, S | 1 |
| Frebourg, T | 1 |
| Fronza, G | 1 |
| Hainaut, P | 1 |
| Thomas, CR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Trial of Preoperative Radiation and Chemotherapy (Paclitaxel, Carboplatin, and Continuous Infusion 5-FU) for Locally Advanced Esophageal Cancer[NCT00022139] | Phase 2 | 56 participants (Actual) | Interventional | 2002-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for amifostine anhydrous and Esophageal Neoplasms
| Article | Year |
|---|---|
Aggressive multimodality therapy for patients with locally advanced esophageal cancer: is there a role for amifostine?
Topics: Amifostine; Antineoplastic Agents; Clinical Trials as Topic; Combined Modality Therapy; Esophageal N | 2003 |
4 other studies available for amifostine anhydrous and Esophageal Neoplasms
| Article | Year |
|---|---|
Combined modality treatment with full-dose chemotherapy and concomitant boost radiotherapy for advanced head and neck carcinoma.
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2005 |
Tolerability of the cytoprotective agent amifostine in elderly patients receiving chemotherapy: a comparative study.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Amifostine; Antihypertensive Agents; Antineoplastic Com | 2001 |
Amifostine (WR2721) restores transcriptional activity of specific p53 mutant proteins in a yeast functional assay.
Topics: Amifostine; Amino Acid Substitution; Animals; Cloning, Molecular; Codon; Esophageal Neoplasms; Gene | 2001 |
Esophageal cancer and the esophagus: challenges and potential strategies for selective cytoprotection of the tumor-bearing organ during cancer treatment.
Topics: Amifostine; Antineoplastic Agents; Combined Modality Therapy; Esophageal Neoplasms; Esophagitis; Eso | 2002 |